Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag

Mannkind Corporation

MNKD Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of MNKD by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
MNKD Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
MNKD Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
MNKD Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes in MNKD holdings by institutional investors

Quarterly net insider trading by MNKD's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

  • $10,000 Jul 20, 2026 Issue: Medicare/Medicaid Health Issues Defense
  • $30,000 Oct 20, 2023 Issue: Health Issues
  • $30,000 Jan 19, 2023 Issue: Health Issues
  • $30,000 Oct 18, 2022 Issue: Health Issues
  • $20,000 Apr 20, 2022 Issue: Health Issues
  • $30,000 Jan 20, 2022 Issue: Health Issues
  • $30,000 Oct 20, 2021 Issue: Medicare/Medicaid
  • $30,000 Jul 21, 2021 Issue: Medicare/Medicaid
  • $30,000 Jun 22, 2021 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs

Former government officials who have lobbied for MNKD

7 former government officials from 5 congressional offices at 2 lobbying firms have lobbied for MNKD, most recently Jul 20, 2026.

  • Mike Kelly
    John Ray House Legislative Assistant, Rep. Mike Kelly Formerly with Mike Kelly · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Lamar Alexander
    John Herzog Senate Health Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President Formerly with Lamar Alexander · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Lamar Alexander
    Brett Meeks Senate Deputy Health Policy Director, Senate Committee on Health, Education, Labor and Pensions; Deputy Press Secretary, Office of Senator Lamar Alexander Formerly with Lamar Alexander · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • John Cornyn
    Laura Kemper Senate Counsel, Sen. John Cornyn; Deputy Assistant Secretary for Legislation, U.S. Department of Health and Human Services; Counselor to the Secretary, U.S. Department of Health and Human Services Formerly with John Cornyn · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Marsha Blackburn
    Keith Studdard House Legislative Director, Rep. Marsha Blackburn Formerly with Marsha Blackburn · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Cathy McMorris Rodgers
    Kristin Fritsch House Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Senior Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Professional Staff Member House Committee on Energy and Commerce Formerly with Cathy McMorris Rodgers · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Benjamin Mason House New Communications Director, Rep. David Young January 2017 - June 2017 Formerly David Young January · THE KPM GROUP DC LLC · May 27, 2021

MNKD Estimated quarterly lobbying spending

MNKD Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
MNKD Income Statement
MNKD Balance Sheet
MNKD Cash Flow
U.S. Patents

New MNKD patent grants

  • Patent Title: Inhaler Jun. 18, 2019
  • Patent Title: Inhaler Feb. 26, 2019
  • Patent Title: Inhaler Nov. 20, 2018
  • Patent Title: Inhaler Jul. 31, 2018
  • Patent Title: Inhaler Jul. 24, 2018
  • Patent Title: Inhaler Jul. 24, 2018
  • Patent Title: Apparatus, system and method for measuring resistance of an inhaler May. 29, 2018
  • Patent Title: Formation of n-protected bis-3,6-(4-aminobutyl)-2, 5-diketopiperazine through a cyclic alpha-n-protected amino ester Apr. 17, 2018
  • Patent Title: Use of ultrarapid acting insulin Apr. 17, 2018
  • Patent Title: Heat-stable dry powder pharmaceutical compositions and methods Mar. 27, 2018
  • Patent Title: Mouthpiece cover Nov. 07, 2017
  • Patent Title: Dry powder drug delivery system and methods Oct. 31, 2017
  • Patent Title: Potentiation of glucose elimination Oct. 31, 2017
  • Patent Title: Catalysis of diketopiperazine synthesis Oct. 24, 2017
  • Patent Title: Powder dispensing and sensing apparatus and methods Sep. 26, 2017
  • Patent Title: Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents Aug. 01, 2017
  • Patent Title: Apparatus and method for simulating inhalation efforts Jul. 18, 2017
  • Patent Title: Inhalation apparatus Jul. 11, 2017
  • Patent Title: Ire-1α inhibitors Jul. 04, 2017
  • Patent Title: Diketopiperazine salts for drug delivery and related methods Jun. 13, 2017
  • Patent Title: Dry powder drug delivery system and methods May. 30, 2017
  • Patent Title: Substituted diketopiperazine analogs for use as drug delivery agents May. 23, 2017
  • Patent Title: Diketopiperazine microparticles with defined specific surface areas Apr. 25, 2017
  • Patent Title: Determining percent solids in suspension using raman spectroscopy Apr. 18, 2017
  • Patent Title: Methods and compositions for treating pain Apr. 04, 2017
  • Patent Title: Use of ultrarapid acting insulin Mar. 21, 2017
  • Patent Title: Apparatus and method for cryogranulating a pharmaceutical composition Feb. 14, 2017
  • Patent Title: Ire-1α inhibitors Jan. 17, 2017
  • Patent Title: Dry powder inhaler and system for drug delivery Dec. 06, 2016
  • Patent Title: Mouthpiece cover Nov. 08, 2016
  • Patent Title: Dry powder inhaler and system for drug delivery Sep. 20, 2016
  • Patent Title: Increasing drug affinity for crystalline microparticle surfaces Sep. 20, 2016
  • Patent Title: Formation of n-protected bis-3,6-(4-aminoalkyl)-2,5,diketopiperazine Aug. 16, 2016
  • Patent Title: Inhaler device Jan. 22, 2013
  • Patent Title: Blister packaging Dec. 04, 2012
  • Patent Title: Cartridge for a dry powder inhaler Jul. 31, 2012
  • Patent Title: Blister packaging Aug. 16, 2011
  • Patent Title: Dry powder inhaler Apr. 26, 2011
  • Patent Title: Dry powder inhaler Apr. 26, 2011
  • Patent Title: Dry powder inhaler Apr. 26, 2011
  • Patent Title: Dry powder inhaler Mar. 29, 2011
  • Patent Title: Dry powder inhaler Mar. 29, 2011
  • Patent Title: Dry powder inhaler Mar. 29, 2011
  • Patent Title: Dry powder inhaler Dec. 28, 2010
  • Patent Title: Dry powder inhaler Dec. 28, 2010
  • Patent Title: Dry powder inhaler Dec. 28, 2010
  • Patent Title: Dry powder inhaler Dec. 21, 2010
  • Patent Title: Dry powder inhaler Dec. 21, 2010
  • Patent Title: Dry powder inhaler Apr. 27, 2010
  • Patent Title: Cartridge for a dry powder inhaler Apr. 13, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to MNKD from public contracts

MNKD News

Recent insights relating to MNKD

CNBC Recommendations

Recent picks made for MNKD stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MNKD

MNKD Analyst Ratings

MNKD Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
MNKD Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $MNKD stock a Buy, Sell, or Hold?

  • What is the price target for $MNKD stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

MNKD Top Shareholders
Shareholder
Shares Held
MNKD Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $MNKD stock?

  • Who owns the most shares of $MNKD stock?

  • What funds own $MNKD stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

MNKD Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view MNKD Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About MNKD

MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

  • Address Danbury, CT
  • Market Cap 1.1 billion
  • Employees 592
  • Industrial Classification Pharmaceutical Preparations

Mannkind Corporation (MNKD) Historical Stock Prices

Mannkind Corporation (MNKD) closed at $3.49 on September 22, 2026. Over the past year its adjusted close ranged from $2.28 to $6.21. Daily prices go back to January 2, 2014, 3,198 trading days in all.

  • 1 month-15.90%
  • 3 months-11.20%
  • Year to date-38.45%
  • 1 year-37.34%
  • 3 years-14.04%
  • 5 years-26.53%
  • Max-86.85%
See every congressional and insider trade on the MNKD price chart

Quiver Premium charts MNKD's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 22, 2026 3.53 3.55 3.25 3.49 3.49 16,303,712
Sep 21, 2026 3.55 3.62 3.47 3.50 3.50 4,527,405
Sep 18, 2026 3.59 3.62 3.50 3.54 3.54 5,513,382
Sep 17, 2026 3.61 3.68 3.53 3.58 3.58 2,733,344
Sep 16, 2026 3.57 3.61 3.52 3.55 3.55 2,228,278
Sep 15, 2026 3.74 3.75 3.54 3.56 3.56 3,698,125
Sep 14, 2026 3.76 3.84 3.73 3.75 3.75 3,129,363
Sep 11, 2026 3.83 3.85 3.73 3.75 3.75 2,469,876
Sep 10, 2026 3.90 3.90 3.76 3.79 3.79 3,209,561
Sep 9, 2026 4.16 4.36 3.92 3.94 3.94 5,192,525
Sep 8, 2026 4.00 4.32 4.00 4.16 4.16 4,930,914
Sep 4, 2026 3.92 4.09 3.92 4.06 4.06 2,807,581
Sep 3, 2026 4.05 4.07 3.96 3.96 3.96 2,331,113
Sep 2, 2026 3.96 4.09 3.96 4.04 4.04 2,590,708
Sep 1, 2026 3.97 4.03 3.95 3.98 3.98 2,234,752
Aug 31, 2026 3.94 4.02 3.90 4.01 4.01 2,805,985
Aug 28, 2026 4.06 4.08 3.93 3.95 3.95 1,990,144
Aug 27, 2026 4.05 4.12 4.04 4.06 4.06 2,068,822
Aug 26, 2026 4.16 4.19 4.05 4.09 4.09 1,766,310
Aug 25, 2026 4.10 4.24 4.10 4.16 4.16 3,193,655
Aug 24, 2026 4.13 4.14 4.06 4.07 4.07 2,812,485
Aug 21, 2026 4.28 4.36 4.11 4.15 4.15 3,204,974
Aug 20, 2026 4.35 4.36 4.13 4.26 4.26 3,415,966
Aug 19, 2026 4.10 4.40 4.10 4.39 4.39 5,435,477
Aug 18, 2026 3.87 4.10 3.87 4.07 4.07 4,600,594
Aug 17, 2026 3.85 3.94 3.80 3.90 3.90 3,322,307
Aug 14, 2026 3.74 3.85 3.69 3.85 3.85 2,855,400
Aug 13, 2026 3.88 3.90 3.63 3.73 3.73 5,239,892
Aug 12, 2026 3.86 3.92 3.83 3.85 3.85 3,055,998
Aug 11, 2026 3.91 3.98 3.81 3.84 3.84 4,497,586
Aug 10, 2026 4.07 4.08 3.88 3.93 3.93 4,157,384
Aug 7, 2026 3.91 4.15 3.85 4.11 4.11 5,048,122
Aug 6, 2026 3.81 3.93 3.69 3.89 3.89 9,306,198
Aug 5, 2026 3.92 4.14 3.90 4.10 4.10 6,833,549
Aug 4, 2026 3.82 4.00 3.78 3.96 3.96 5,118,134
Aug 3, 2026 3.96 3.96 3.78 3.80 3.80 5,276,519
Jul 31, 2026 4.09 4.14 3.85 3.91 3.91 5,404,120
Jul 30, 2026 3.90 4.12 3.88 4.11 4.11 4,140,742
Jul 29, 2026 3.90 3.96 3.82 3.85 3.85 3,587,211
Jul 28, 2026 3.98 4.00 3.84 3.91 3.91 3,657,168
Jul 27, 2026 4.21 4.24 3.95 3.95 3.95 5,325,676
Jul 24, 2026 4.06 4.23 3.98 4.13 4.13 9,444,208
Jul 23, 2026 3.73 3.91 3.71 3.89 3.89 2,941,996
Jul 22, 2026 4.06 4.07 3.81 3.84 3.84 5,543,073
Jul 21, 2026 3.96 4.23 3.96 4.05 4.05 4,403,386
Jul 20, 2026 4.03 4.10 3.98 3.98 3.98 3,024,894
Jul 17, 2026 4.00 4.14 3.95 4.03 4.03 3,508,984
Jul 16, 2026 4.06 4.20 4.03 4.04 4.04 3,299,606
Jul 15, 2026 3.90 4.12 3.87 4.09 4.09 5,611,449
Jul 14, 2026 4.07 4.07 3.85 3.88 3.88 4,649,492
Jul 13, 2026 4.04 4.14 3.94 4.04 4.04 4,043,863
Jul 10, 2026 4.12 4.22 3.98 4.09 4.09 4,250,071
Jul 9, 2026 4.24 4.29 4.13 4.14 4.14 3,358,418
Jul 8, 2026 4.16 4.32 4.07 4.25 4.25 6,892,667
Jul 7, 2026 4.33 4.41 4.16 4.22 4.22 3,394,138
Jul 6, 2026 4.48 4.55 4.25 4.27 4.27 4,082,954
Jul 2, 2026 4.09 4.54 4.08 4.52 4.52 9,573,416
Jul 1, 2026 4.27 4.30 4.05 4.05 4.05 2,722,590
Jun 30, 2026 4.25 4.37 4.18 4.26 4.26 6,822,023
Jun 29, 2026 4.10 4.28 4.06 4.24 4.24 3,420,157
Jun 26, 2026 3.90 4.19 3.90 4.14 4.14 11,868,005
Jun 25, 2026 3.85 3.95 3.77 3.93 3.93 3,234,598
Jun 24, 2026 3.94 3.99 3.80 3.84 3.84 4,483,049
Jun 23, 2026 3.86 3.94 3.85 3.93 3.93 2,985,900
Jun 22, 2026 3.95 4.06 3.88 3.89 3.89 3,563,036
Jun 18, 2026 4.00 4.02 3.83 3.94 3.94 16,622,952
Jun 17, 2026 3.89 4.02 3.88 3.92 3.92 3,665,280
Jun 16, 2026 4.00 4.04 3.84 3.87 3.87 3,164,062
Jun 15, 2026 3.73 4.05 3.70 4.00 4.00 5,605,230
Jun 12, 2026 3.75 3.81 3.64 3.66 3.66 3,844,283
Jun 11, 2026 3.63 3.79 3.55 3.75 3.75 4,071,347
Jun 10, 2026 3.50 3.74 3.48 3.63 3.63 4,478,266
Jun 9, 2026 3.44 3.60 3.41 3.57 3.57 4,907,688
Jun 8, 2026 3.45 3.52 3.38 3.39 3.39 2,349,399
Jun 5, 2026 3.53 3.53 3.39 3.40 3.40 3,245,421
Jun 4, 2026 3.35 3.53 3.34 3.52 3.52 3,519,408
Jun 3, 2026 3.43 3.52 3.30 3.36 3.36 3,494,664
Jun 2, 2026 3.49 3.58 3.41 3.43 3.43 7,025,035
Jun 1, 2026 3.76 3.81 3.41 3.53 3.53 8,345,288
May 29, 2026 3.66 3.94 3.51 3.77 3.77 20,391,857
May 28, 2026 3.57 3.67 3.47 3.64 3.64 5,464,380
May 27, 2026 3.53 3.62 3.44 3.55 3.55 3,581,373
May 26, 2026 3.43 3.56 3.42 3.53 3.53 3,704,851
May 22, 2026 3.32 3.46 3.32 3.38 3.38 4,608,165
May 21, 2026 3.20 3.35 3.14 3.31 3.31 3,002,120
May 20, 2026 3.00 3.27 2.99 3.25 3.25 5,175,749
May 19, 2026 2.99 3.01 2.93 2.96 2.96 4,549,095
May 18, 2026 3.13 3.17 2.97 2.99 2.99 5,152,103
May 15, 2026 3.19 3.21 3.07 3.09 3.09 4,962,233
May 14, 2026 3.21 3.25 3.14 3.22 3.22 3,592,242
May 13, 2026 3.28 3.28 3.11 3.21 3.21 4,510,656
May 12, 2026 3.34 3.43 3.25 3.28 3.28 5,514,111
May 11, 2026 3.52 3.60 3.33 3.36 3.36 7,537,876
May 8, 2026 3.56 3.68 3.40 3.52 3.52 9,544,170
May 7, 2026 3.32 3.88 3.26 3.55 3.55 16,013,770
May 6, 2026 3.44 4.29 3.40 3.56 3.56 36,837,694
May 5, 2026 2.84 2.89 2.83 2.86 2.86 3,029,569
May 4, 2026 2.84 2.88 2.78 2.81 2.81 3,684,491
May 1, 2026 2.83 2.87 2.78 2.84 2.84 2,797,413
Apr 30, 2026 2.75 2.85 2.74 2.83 2.83 3,616,946
Apr 29, 2026 2.77 2.77 2.68 2.75 2.75 3,009,807
Apr 28, 2026 2.67 2.81 2.65 2.79 2.79 5,621,369
Apr 27, 2026 2.71 2.75 2.59 2.63 2.63 3,928,618
Apr 24, 2026 2.72 2.76 2.66 2.70 2.70 2,776,174
Apr 23, 2026 2.73 2.75 2.66 2.71 2.71 2,944,509
Apr 22, 2026 2.75 2.76 2.66 2.74 2.74 3,928,189
Apr 21, 2026 2.97 2.98 2.69 2.70 2.70 5,216,886
Apr 20, 2026 2.85 2.97 2.79 2.92 2.92 4,068,845
Apr 17, 2026 2.78 2.85 2.76 2.84 2.84 3,549,751
Apr 16, 2026 2.77 2.77 2.68 2.75 2.75 3,025,612
Apr 15, 2026 2.71 2.77 2.67 2.77 2.77 3,212,572
Apr 14, 2026 2.66 2.75 2.64 2.74 2.74 3,598,989
Apr 13, 2026 2.57 2.67 2.56 2.64 2.64 2,558,237
Apr 10, 2026 2.60 2.64 2.55 2.57 2.57 3,100,447
Apr 9, 2026 2.59 2.65 2.56 2.56 2.56 3,291,189
Apr 8, 2026 2.67 2.68 2.56 2.61 2.61 4,471,317
Apr 7, 2026 2.53 2.58 2.42 2.57 2.57 3,022,388
Apr 6, 2026 2.47 2.56 2.45 2.56 2.56 3,175,559
Apr 2, 2026 2.48 2.51 2.42 2.50 2.50 3,758,383
Apr 1, 2026 2.49 2.58 2.45 2.54 2.54 3,478,444
Mar 31, 2026 2.42 2.48 2.35 2.45 2.45 4,843,967
Mar 30, 2026 2.33 2.42 2.29 2.37 2.37 5,517,104
Mar 27, 2026 2.27 2.32 2.23 2.28 2.28 5,604,328
Mar 26, 2026 2.25 2.37 2.23 2.30 2.30 6,357,016
Mar 25, 2026 2.34 2.45 2.25 2.28 2.28 6,324,224
Mar 24, 2026 2.41 2.41 2.25 2.29 2.29 14,761,521
Mar 23, 2026 2.54 2.59 2.39 2.44 2.44 6,293,253
Mar 20, 2026 2.54 2.54 2.41 2.47 2.47 19,093,757
Mar 19, 2026 2.57 2.60 2.48 2.52 2.52 4,640,831
Mar 18, 2026 2.69 2.73 2.59 2.61 2.61 4,763,631
Mar 17, 2026 2.76 2.76 2.69 2.73 2.73 3,652,065
Mar 16, 2026 2.77 2.85 2.74 2.77 2.77 5,392,892
Mar 13, 2026 2.81 2.81 2.70 2.77 2.77 3,814,320
Mar 12, 2026 2.75 2.88 2.69 2.82 2.82 6,205,862
Mar 11, 2026 2.81 2.92 2.71 2.82 2.82 7,294,713
Mar 10, 2026 2.72 2.74 2.57 2.61 2.61 4,987,716
Mar 9, 2026 2.63 2.68 2.52 2.68 2.68 6,620,509
Mar 6, 2026 2.81 2.81 2.58 2.61 2.61 9,457,117
Mar 5, 2026 2.94 2.97 2.81 2.83 2.83 6,384,217
Mar 4, 2026 2.96 3.01 2.87 2.95 2.95 7,061,400
Mar 3, 2026 2.95 3.02 2.83 2.92 2.92 5,146,731
Mar 2, 2026 3.23 3.25 2.95 3.04 3.04 10,456,411
Feb 27, 2026 3.15 3.37 3.14 3.28 3.28 8,899,354
Feb 26, 2026 3.70 3.72 2.94 3.24 3.24 33,343,507
Feb 25, 2026 5.54 5.55 3.29 3.50 3.50 36,584,525
Feb 24, 2026 5.59 5.74 5.50 5.54 5.54 1,993,979
Feb 23, 2026 5.55 5.70 5.54 5.57 5.57 1,841,850
Feb 20, 2026 5.51 5.67 5.46 5.54 5.54 2,900,820
Feb 19, 2026 5.42 5.56 5.39 5.53 5.53 1,889,284
Feb 18, 2026 5.51 5.58 5.41 5.44 5.44 2,207,231
Feb 17, 2026 5.60 5.72 5.54 5.54 5.54 1,888,141
Feb 13, 2026 5.66 5.76 5.62 5.66 5.66 2,065,168
Feb 12, 2026 5.73 5.76 5.54 5.63 5.63 1,524,673
Feb 11, 2026 5.82 5.87 5.65 5.74 5.74 1,726,764
Feb 10, 2026 5.93 6.05 5.79 5.83 5.83 2,037,413
Feb 9, 2026 5.75 5.93 5.73 5.91 5.91 2,515,296
Feb 6, 2026 5.59 5.86 5.53 5.78 5.78 3,012,579
Feb 5, 2026 5.75 5.87 5.47 5.51 5.51 3,208,445
Feb 4, 2026 6.25 6.27 5.75 5.78 5.78 4,940,451
Feb 3, 2026 6.00 6.22 5.98 6.21 6.21 4,422,774
Feb 2, 2026 5.75 6.03 5.62 6.01 6.01 4,617,311
Jan 30, 2026 5.78 5.90 5.72 5.78 5.78 4,275,162
Jan 29, 2026 5.61 5.93 5.61 5.79 5.79 4,335,903
Jan 28, 2026 5.58 5.93 5.52 5.64 5.64 4,863,946
Jan 27, 2026 5.54 5.63 5.42 5.59 5.59 2,784,184
Jan 26, 2026 5.47 5.63 5.43 5.58 5.58 4,283,580
Jan 23, 2026 5.88 5.95 5.46 5.46 5.46 4,518,395
Jan 22, 2026 5.74 6.05 5.69 5.91 5.91 5,723,763
Jan 21, 2026 5.48 5.74 5.46 5.71 5.71 4,156,524
Jan 20, 2026 5.07 5.50 5.03 5.49 5.49 5,256,158
Jan 16, 2026 5.59 5.61 5.19 5.21 5.21 6,745,018
Jan 15, 2026 5.61 5.68 5.55 5.58 5.58 3,947,257
Jan 14, 2026 5.62 5.64 5.55 5.61 5.61 2,595,070
Jan 13, 2026 5.80 5.80 5.63 5.64 5.64 2,905,794
Jan 12, 2026 5.82 5.84 5.74 5.77 5.77 3,684,990
Jan 9, 2026 6.08 6.11 5.83 5.85 5.85 2,602,684
Jan 8, 2026 5.90 6.51 5.89 6.01 6.01 7,484,330
Jan 7, 2026 5.66 5.97 5.63 5.85 5.85 5,420,434
Jan 6, 2026 5.56 5.76 5.55 5.62 5.62 2,995,797
Jan 5, 2026 5.61 5.64 5.53 5.62 5.62 2,620,972
Jan 2, 2026 5.73 5.73 5.58 5.60 5.60 2,733,096
Dec 31, 2025 5.66 5.73 5.62 5.67 5.67 2,397,182
Dec 30, 2025 5.78 5.78 5.55 5.66 5.66 3,515,159
Dec 29, 2025 5.79 5.82 5.73 5.77 5.77 1,640,983
Dec 26, 2025 5.92 5.92 5.76 5.79 5.79 2,430,916
Dec 24, 2025 5.96 5.96 5.88 5.93 5.93 907,366
Dec 23, 2025 5.98 6.01 5.84 5.93 5.93 2,503,597
Dec 22, 2025 5.86 6.07 5.84 5.99 5.99 3,040,125
Dec 19, 2025 5.96 6.12 5.80 5.84 5.84 13,714,216
Dec 18, 2025 6.00 6.03 5.88 5.97 5.97 3,231,118
Dec 17, 2025 5.88 6.14 5.88 5.97 5.97 3,595,131
Dec 16, 2025 5.96 6.02 5.88 5.91 5.91 2,832,482
Dec 15, 2025 5.95 6.00 5.83 5.94 5.94 3,004,439
Dec 12, 2025 5.83 6.01 5.79 5.94 5.94 3,389,533
Dec 11, 2025 5.82 5.91 5.75 5.81 5.81 3,697,705
Dec 10, 2025 5.80 5.85 5.68 5.84 5.84 3,332,532
Dec 9, 2025 5.69 5.89 5.63 5.77 5.77 4,410,815
Dec 8, 2025 5.75 5.76 5.58 5.63 5.63 2,547,585
Dec 5, 2025 5.70 5.75 5.65 5.68 5.68 1,782,170
Dec 4, 2025 5.60 5.81 5.58 5.71 5.71 2,362,112
Dec 3, 2025 5.62 5.79 5.51 5.59 5.59 3,395,801
Dec 2, 2025 5.45 5.68 5.42 5.59 5.59 4,130,201
Dec 1, 2025 5.35 5.47 5.30 5.43 5.43 2,669,507
Nov 28, 2025 5.42 5.42 5.30 5.35 5.35 797,355
Nov 26, 2025 5.34 5.40 5.28 5.38 5.38 2,056,728
Nov 25, 2025 5.16 5.37 5.13 5.36 5.36 2,504,281
Nov 24, 2025 5.16 5.19 5.07 5.13 5.13 2,315,756
Nov 21, 2025 4.96 5.07 4.95 5.03 5.03 2,670,496
Nov 20, 2025 5.05 5.09 4.95 4.97 4.97 2,470,387
Nov 19, 2025 5.04 5.05 4.93 5.00 5.00 2,732,925
Nov 18, 2025 4.95 5.09 4.93 5.06 5.06 3,763,420
Nov 17, 2025 5.03 5.14 4.97 4.98 4.98 3,497,488
Nov 14, 2025 5.00 5.24 5.00 5.06 5.06 3,460,694
Nov 13, 2025 5.27 5.29 5.05 5.07 5.07 3,826,993
Nov 12, 2025 5.30 5.35 5.16 5.25 5.25 2,814,158
Nov 11, 2025 5.34 5.41 5.17 5.25 5.25 3,122,845
Nov 10, 2025 5.20 5.50 4.95 5.42 5.42 8,187,580
Nov 7, 2025 5.60 5.67 5.52 5.63 5.63 3,176,488
Nov 6, 2025 6.13 6.13 5.66 5.70 5.70 4,316,092
Nov 5, 2025 5.96 6.24 5.68 6.06 6.06 10,930,118
Nov 4, 2025 5.42 5.60 5.41 5.48 5.48 3,882,738
Nov 3, 2025 5.60 5.68 5.45 5.48 5.48 3,273,619
Oct 31, 2025 5.51 5.66 5.46 5.59 5.59 3,411,412
Oct 30, 2025 5.54 5.72 5.43 5.55 5.55 4,207,079
Oct 29, 2025 5.29 5.67 5.24 5.54 5.54 7,829,664
Oct 28, 2025 5.37 5.45 5.26 5.30 5.30 2,930,870
Oct 27, 2025 5.30 5.50 5.28 5.42 5.42 2,689,055
Oct 24, 2025 5.52 5.52 5.30 5.31 5.31 2,975,528
Oct 23, 2025 5.53 5.61 5.46 5.49 5.49 3,619,189
Oct 22, 2025 5.50 5.62 5.46 5.53 5.53 4,363,073
Oct 21, 2025 5.49 5.55 5.35 5.51 5.51 3,753,440
Oct 20, 2025 5.58 5.58 5.28 5.49 5.49 3,794,419
Oct 17, 2025 5.30 5.52 5.20 5.47 5.47 5,619,699
Oct 16, 2025 5.23 5.39 5.22 5.35 5.35 5,327,227
Oct 15, 2025 5.10 5.27 5.06 5.23 5.23 3,910,493
Oct 14, 2025 5.05 5.15 5.02 5.10 5.10 4,296,763
Oct 13, 2025 4.92 5.15 4.89 5.10 5.10 4,517,687
Oct 10, 2025 5.20 5.20 4.79 4.88 4.88 8,955,318
Oct 9, 2025 5.47 5.70 5.02 5.14 5.14 8,995,741
Oct 8, 2025 5.67 5.72 5.43 5.44 5.44 4,756,660
Oct 7, 2025 5.69 5.75 5.61 5.65 5.65 3,618,983
Oct 6, 2025 5.75 5.85 5.65 5.66 5.66 3,391,541
Oct 3, 2025 5.50 5.89 5.49 5.76 5.76 5,126,932
Oct 2, 2025 5.41 5.50 5.34 5.49 5.49 2,638,759
Oct 1, 2025 5.39 5.55 5.33 5.38 5.38 3,525,109
Sep 30, 2025 5.36 5.43 5.34 5.37 5.37 2,525,015
Sep 29, 2025 5.58 5.62 5.33 5.39 5.39 3,596,234
Sep 26, 2025 5.34 5.54 5.29 5.53 5.53 6,079,938
Sep 25, 2025 5.31 5.37 5.18 5.33 5.33 4,610,394
Sep 24, 2025 5.35 5.43 5.29 5.33 5.33 3,598,016
Sep 23, 2025 5.55 5.55 5.28 5.35 5.35 4,628,916
Sep 22, 2025 5.48 5.64 5.39 5.57 5.57 2,996,823

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Mannkind Corporation Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at MNKD, per a recent SEC DEF 14A filing. We estimate that the median employee at MANNKIND CORP is paid $176,105.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation